News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
756,559 Results
Type
Article (53958)
Company Profile (473)
Press Release (702128)
Section
Business (218040)
Career Advice (2869)
Deals (37408)
Drug Delivery (120)
Drug Development (87158)
Employer Resources (186)
FDA (17116)
Job Trends (16081)
News (370058)
Policy (35627)
Tag
2024 BioCapital Digital (11)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (11)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (11)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (19)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (9)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (11)
2024 Pharm Country Digital (8)
2024 Pharm Country Standard (7)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2911)
Academic (1)
Accelerated approval (3)
Adcomms (27)
Allergies (84)
Alliances (53361)
ALS (91)
Alzheimer's disease (1449)
Antibody-drug conjugate (ADC) (131)
Approvals (17079)
Artificial intelligence (255)
Autoimmune disease (17)
Automation (14)
Bankruptcy (389)
Best Places to Work (12332)
BIOSECURE Act (20)
Biosimilars (109)
Biotechnology (355)
Bladder cancer (63)
Brain cancer (28)
Breast cancer (262)
Cancer (2058)
Cardiovascular disease (169)
Career advice (2404)
Career pathing (33)
CAR-T (152)
Cell therapy (425)
Cervical cancer (17)
Clinical research (70221)
Collaboration (815)
Compensation (456)
Complete response letters (27)
COVID-19 (2802)
CRISPR (42)
C-suite (217)
Cystic fibrosis (104)
Data (1901)
Decentralized trials (2)
Denatured (32)
Depression (48)
Diabetes (260)
Diagnostics (6685)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (117)
Drug pricing (118)
Drug shortages (28)
Duchenne muscular dystrophy (87)
Earnings (89272)
Editorial (38)
Employer branding (24)
Employer resources (159)
Events (120717)
Executive appointments (664)
FDA (18227)
Featured Employer (59)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (723)
Gene editing (106)
Generative AI (23)
Gene therapy (308)
GLP-1 (786)
Government (4849)
Grass and pollen (4)
Guidances (48)
Healthcare (20191)
Huntington's disease (24)
IgA nephropathy (25)
Immunology and inflammation (121)
Indications (27)
Infectious disease (2939)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (50)
Intellectual property (85)
Interviews (556)
IPO (17176)
IRA (49)
Job creations (4219)
Job search strategy (1986)
Kidney cancer (10)
Labor market (33)
Layoffs (509)
Leadership (20)
Legal (8733)
Liver cancer (76)
Lung cancer (297)
Lymphoma (131)
Machine learning (2)
Management (62)
Manufacturing (286)
MASH (65)
Medical device (14002)
Medtech (14007)
Mergers & acquisitions (20684)
Metabolic disorders (692)
Multiple sclerosis (73)
NASH (23)
Neurodegenerative disease (92)
Neuropsychiatric disorders (31)
Neuroscience (1961)
NextGen: Class of 2025 (7249)
Non-profit (4897)
Northern California (2405)
Now hiring (37)
Obesity (378)
Opinion (257)
Ovarian cancer (73)
Pain (85)
Pancreatic cancer (78)
Parkinson's disease (137)
Partnered (18)
Patents (209)
Patient recruitment (94)
Peanut (50)
People (62226)
Pharmaceutical (94)
Pharmacy benefit managers (20)
Phase I (21879)
Phase II (30843)
Phase III (22956)
Pipeline (946)
Podcasts (95)
Policy (128)
Postmarket research (2939)
Preclinical (9374)
Press Release (70)
Prostate cancer (94)
Psychedelics (38)
Radiopharmaceuticals (265)
Rare diseases (384)
Real estate (6482)
Recruiting (72)
Regulatory (24111)
Reports (47)
Research institute (2582)
Resumes & cover letters (454)
Rett syndrome (3)
RNA editing (2)
RSV (41)
Schizophrenia (72)
Series A (129)
Series B (82)
Service/supplier (13)
Sickle cell disease (55)
Southern California (2094)
Special edition (17)
Spinal muscular atrophy (158)
Sponsored (31)
Startups (3933)
State (2)
Stomach cancer (15)
Supply chain (64)
The Weekly (61)
United States (21643)
Vaccines (736)
Venture capitalists (39)
Webinars (13)
Weight loss (273)
Women's health (37)
Worklife (18)
Date
Today (160)
Last 7 days (625)
Last 30 days (3061)
Last 365 days (35705)
2025 (7796)
2024 (37239)
2023 (42046)
2022 (53337)
2021 (58018)
2020 (56723)
2019 (49934)
2018 (37763)
2017 (34839)
2016 (34730)
2015 (40810)
2014 (34949)
2013 (30241)
2012 (32224)
2011 (32693)
2010 (30934)
Location
Africa (925)
Alabama (55)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (43428)
Australia (7744)
California (5583)
Canada (1877)
China (480)
Colorado (247)
Connecticut (270)
Delaware (129)
Europe (96155)
Florida (820)
Georgia (192)
Idaho (61)
Illinois (527)
India (23)
Indiana (296)
Iowa (10)
Japan (138)
Kansas (103)
Kentucky (26)
Louisiana (8)
Maine (60)
Maryland (868)
Massachusetts (4288)
Michigan (216)
Minnesota (384)
Mississippi (2)
Missouri (82)
Montana (30)
Nebraska (25)
Nevada (56)
New Hampshire (68)
New Jersey (1586)
New Mexico (31)
New York (1599)
North Carolina (1024)
North Dakota (7)
Northern California (2405)
Ohio (196)
Oklahoma (14)
Oregon (39)
Pennsylvania (1249)
Puerto Rico (10)
Rhode Island (28)
South America (1303)
South Carolina (17)
South Dakota (1)
Southern California (2094)
Tennessee (95)
Texas (829)
Utah (168)
Virginia (135)
Washington D.C. (63)
Washington State (532)
West Virginia (3)
Wisconsin (51)
756,559 Results for "sarepta therapeutics formerly known as avi biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcasts
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations without advisor input; Trump CDC nominee Dave Weldon pulled at last minute; and FDA decisions expected for Alnylam’s Amvuttra in ATTR-CM and Milestone’s etripamil in tachycardia.
March 19, 2025
·
2 min read
·
Heather McKenzie
Editorial
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.
December 4, 2024
·
3 min read
·
Annalee Armstrong
Gene Therapy
Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies
After a patient taking the Duchenne muscular dystrophy gene therapy Elevydis died of liver injury, Sarepta will update the label to reflect the safety signal.
March 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
Earnings
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter of 2024, reflecting the biotech’s “world-class” execution, according to BMO Capital Markets analysts.
January 14, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting
With Sarepta’s gene therapy Elevidys now available to a majority of Duchenne muscular dystrophy patients, experts express cautious optimism while emphasizing the need for further data.
October 28, 2024
·
6 min read
·
Heather McKenzie
Press Releases
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
February 17, 2025
·
4 min read
Press Releases
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
February 10, 2025
·
6 min read
Press Releases
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
February 20, 2025
·
5 min read
1 of 75,656
Next
